Immunotherapy and Targeted Therapy Flashcards
6 cards from real Mesothelioma Therapy practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 6 Immunotherapy and Targeted Therapy flashcards as text
Mesothelin is a target in mesothelioma because it is:
Answer: Overexpressed on mesothelioma cell surfaces
Mesothelin is highly overexpressed on the surface of mesothelioma cells, making it an attractive target for antibody-based therapies.
Amatuximab is an experimental targeted therapy for mesothelioma that targets which protein?
Answer: Mesothelin
Amatuximab is a chimeric anti-mesothelin monoclonal antibody being investigated as a targeted therapy for mesothelin-expressing mesothelioma.
CAR-T cell therapy in mesothelioma research primarily targets which antigen?
Answer: Mesothelin
CAR-T cell therapies for mesothelioma are primarily engineered to target mesothelin, which is abundantly expressed on mesothelioma cells.
Pembrolizumab targets which checkpoint molecule?
Answer: PD-1
Pembrolizumab is a PD-1 inhibitor that blocks the PD-1 receptor, preventing tumor cells from suppressing T-cell activity.
Avelumab differs from nivolumab and pembrolizumab in that it targets:
Answer: PD-L1 on tumor cells
Avelumab is an anti-PD-L1 antibody that targets the PD-L1 ligand on tumor cells, rather than the PD-1 receptor on T cells.
Which targeted mutation makes some mesothelioma patients potentially eligible for PARP inhibitor therapy?
Answer: BAP1 mutation (loss of function)
Loss-of-function mutations in BAP1 may create a homologous recombination deficiency, potentially sensitizing tumors to PARP inhibitors.